Which AI agents work with Endo Consider Thyroxine Treatment Sch Hyperlipidemia?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Who published Endo Consider Thyroxine Treatment Sch Hyperlipidemia?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Consider Thyroxine Treatment Sch Hyperlipidemia by dromlakhani

Name: Endo Consider Thyroxine Treatment Sch Hyperlipidemia
Rating: 4.2 (5 reviews)
Author: dromlakhani

Endo Consider Thyroxine Treatment Sch Hyperlipidemia

Suggests considering thyroxine treatment to reduce LDL-C in patients with subclinical hypothyroidism (TSH <10 mIU/L) and associated hyperlipidemia. Trigger phrases include "Patient with SCH and hyperlipidemia", "TSH between 4-10 mIU/L with elevated lipids", "Considering thyroid treatment for lipid abnormality in mild hypothyroidism".

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Consider thyroxine treatment for subclinical hypothyroidism with associated hyperlipidemia

STEP 1 — Gather Information

Collect TSH level, full lipid panel (LDL-C, HDL-C, triglycerides), assess for symptoms of hypothyroidism, evaluate cardiovascular risk factors, and rule out other causes of hyperlipidemia (e.g., diabetes, nephrotic syndrome, medications). Confirm SCH (TSH 4–10 mIU/L) and hyperlipidemia (elevated LDL-C per local lab norms or >100 mg/dL).

STEP 2 — Rule In / Rule Out

Is TSH between 4 and 10 mIU/L AND LDL-C elevated? If yes, proceed to consider thyroxine treatment; if no, evaluate for overt hypothyroidism, non-thyroidal illness, or alternative lipid-lowering strategies.

STEP 3 — Classify or Stratify

Stratify by baseline LDL-C and cardiovascular risk: higher LDL-C (>130 mg/dL) or presence of ASCVD risk factors favors treatment; lower LDL-C (<100 mg/dL) may warrant lifestyle intervention first.

STEP 4 — Decide

Initiate low-dose levothyroxine (e.g., 25–50 mcg daily) with goal of reducing LDL-C by ~10–15%; recheck TSH and lipid panel in 6–8 weeks to adjust dose and avoid over-treatment (TSH <0.1 mIU/L).

Clinical Guardrails / Mimics / Pitfalls

Do not treat if TSH is normal (<4 mIU/L) or if hyperlipidemia is isolated without SCH; avoid in pregnancy without thyroid dose adjustment; monitor for iatrogenic hyperthyroidism; do not rely solely on thyroxine for lipid control if TSH normalizes but lipids remain elevated; consider statin therapy if LDL-C remains high after euthyroidism.

Concrete Clinical Example

A 58-year-old man with TSH 6.8 mIU/L, LDL-C 160 mg/dL, HDL-C 38 mg/dL, triglycerides 140 mg/dL, no hypothyroid symptoms, is diagnosed with SCH and hyperlipidemia; after discussing benefits, levothyroxine 50 mcg daily is started, and LDL-C drops to 140 mg/dL at 8-week follow-up with TSH 2.1 mIU/L.

Source: Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674

TODO: consider adding scripts/calc.py for the endo-consider-thyroxine-treatment-sch-hyperlipidemia calculator

---name: endo-consider-thyroxine-treatment-sch-hyperlipidemiadescription: Suggests considering thyroxine treatment to reduce LDL-C in patients with subclinical hypothyroidism (TSH <10 mIU/L) and associated hyperlipidemia. Trigger phrases include "Patient with SCH and hyperlipidemia", "TSH between 4-10 mIU/L with elevated lipids", "Considering thyroid treatment for lipid abnormality in mild hypothyroidism".---# Consider thyroxine treatment for subclinical hypothyroidism with associated hyperlipidemia## STEP 1 — Gather InformationCollect TSH level, full lipid panel (LDL-C, HDL-C, triglycerides), assess for symptoms of hypothyroidism, evaluate cardiovascular risk factors, and rule out other causes of hyperlipidemia (e.g., diabetes, nephrotic syndrome, medications). Confirm SCH (TSH 4–10 mIU/L) and hyperlipidemia (elevated LDL-C per local lab norms or >100 mg/dL).## STEP 2 — Rule In / Rule OutIs TSH between 4 and 10 mIU/L AND LDL-C elevated? If yes, proceed to consider thyroxine treatment; if no, evaluate for overt hypothyroidism, non-thyroidal illness, or alternative lipid-lowering strategies.## STEP 3 — Classify or StratifyStratify by baseline LDL-C and cardiovascular risk: higher LDL-C (>130 mg/dL) or presence of ASCVD risk factors favors treatment; lower LDL-C (<100 mg/dL) may warrant lifestyle intervention first.## STEP 4 — DecideInitiate low-dose levothyroxine (e.g., 25–50 mcg daily) with goal of reducing LDL-C by ~10–15%; recheck TSH and lipid panel in 6–8 weeks to adjust dose and avoid over-treatment (TSH <0.1 mIU/L).## Clinical Guardrails / Mimics / PitfallsDo not treat if TSH is normal (<4 mIU/L) or if hyperlipidemia is isolated without SCH; avoid in pregnancy without thyroid dose adjustment; monitor for iatrogenic hyperthyroidism; do not rely solely on thyroxine for lipid control if TSH normalizes but lipids remain elevated; consider statin therapy if LDL-C remains high after euthyroidism.## Concrete Clinical ExampleA 58-year-old man with TSH 6.8 mIU/L, LDL-C 160 mg/dL, HDL-C 38 mg/dL, triglycerides 140 mg/dL, no hypothyroid symptoms, is diagnosed with SCH and hyperlipidemia; after discussing benefits, levothyroxine 50 mcg daily is started, and LDL-C drops to 140 mg/dL at 8-week follow-up with TSH 2.1 mIU/L.**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674> **TODO:** consider adding scripts/calc.py for the endo-consider-thyroxine-treatment-sch-hyperlipidemia calculator

Frequently asked questions